EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis

Song Chen iD, Zhiqiang Wu, Yi Xiao, Xiongying Jiang, Feng Shi, Ning Wang, Fangzeng Lin, Guosheng Tan, Wenquan Zhuang, Yonghui Huang

Therapeutic Advances in Medical Oncology · 2026-07 · 18

DOI: 10.1177/17588359261472766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 31.07.2026. Verfasst von Song Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Postdoctoral Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with hepatocellular carcinoma (HCC) presenting with both portal vein tumor thrombus (PVTT) and pulmonary metastasis (PM) have a particularly poor prognosis and limited treatment options. Hepatic arterial infusion chemotherapy (HAIC)-based combination therapy has shown promising activity in advanced HCC, but evidence in this high-risk population remains limited.

Objectives

To evaluate the efficacy and safety of HAIC combined with lenvatinib and tislelizumab (HLP) in patients with HCC with concurrent PVTT and PM.

Design

Multicenter retrospective cohort study with propensity score matching (PSM).

Methods

Treatment-naïve patients with HCC with concurrent PVTT and PM who received lenvatinib plus tislelizumab (LP), with or without HAIC, between June 2018 and June 2024 were included. PSM was performed to balance baseline characteristics between treatment groups. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).

Results

A total of 262 patients were enrolled, including 114 patients in the HLP group and 148 patients in the LP group. After 1:1 PSM, 96 matched pairs were analyzed. The HLP group achieved significantly longer median OS than the LP group (15.1 vs 7.0 months; hazard ratio (HR), 0.55; 95% confidence interval (CI), 0.40–0.76; p < 0.001) and longer median PFS (7.3 vs 3.7 months; HR, 0.77; 95% CI, 0.56–0.94; p = 0.033). The ORR (47.7% vs 19.8%; p < 0.001) and DCR (86.1% vs 49.0%; p < 0.001) were also significantly higher in the HLP group. Although both all-grade and grade 3/4 treatment-related AEs were more frequent in the HLP group, toxicities were manageable, and no grade 5 AEs were observed.

Conclusion

In patients with HCC with concurrent PVTT and PM, HLP was associated with improved survival outcomes and tumor response compared with lenvatinib plus tislelizumab alone, with a manageable safety profile.

Schlagwörter

Stichwörter der Autor:innen

hepatic arterial infusion chemotherapyhepatocellular carcinomalenvatinibportal vein tumor thrombuspulmonary metastasistislelizumab

Autor:innen und Institutionen

  • Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Interventional Radiology Division, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Department of Radiology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.

ORCID-Profile: Song Chen

Förderung

  • Postdoctoral Science Foundation of China

Zitieren

APA

Chen, S., Wu, Z., Xiao, Y., Jiang, X., Shi, F., Wang, N., Lin, F., Tan, G., Zhuang, W., & Huang, Y. (2026). HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261472766

Vancouver

Chen S, Wu Z, Xiao Y, Jiang X, Shi F, Wang N, et al. HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261472766

BibTeX
@article{Chen2026,
  author = {Chen, Song and Wu, Zhiqiang and Xiao, Yi and Jiang, Xiongying and Shi, Feng and Wang, Ning and Lin, Fangzeng and Tan, Guosheng and Zhuang, Wenquan and Huang, Yonghui},
  title = {HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261472766}
}
Kostenlos starten →